LOW-VOLUME · HOSP-HEAVY

acamprosate Side Effects

acamprosate (also sold as Campral) is a LOW-VOLUME FAERS extract #513 of 524 by FAERS report count. Still opens on HOSP-HEAVY: 48.2% mention hospitalization (144 reports).

Data updated 2026-05-15

299
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

acamprosate: 48.2% mention hospitalization (144 reports). Death stamp DEATH-HEAVY; volume band LOW-VOLUME #513 of 524 by FAERS report count.

Thinner FAERS extract for acamprosate (Campral) (299 reports #513 of 524 by FAERS report count). 48.2% mention hospitalization (144 reports). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2006–2025). Stamps TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.

HYPOTENSION leads 14 of 299 reports

HYPOTENSION
14
ASTHENIA
13
CONDITION AGGRAVATED
13
ACUTE KIDNEY INJURY
12
COMA
12
FATIGUE
11
TOXICITY TO VARIOUS AGENTS
11
DRUG ABUSE
10
HEADACHE
10
BRADYCARDIA
9
CYTOLYTIC HEPATITIS
9
DEPRESSION
9
HEPATIC CYTOLYSIS
9
HYPOGLYCAEMIA
9
NEUTROPENIA
9
OVERDOSE
9
ATRIOVENTRICULAR BLOCK
8

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 108 (40%)
Male 159 (60%)

Age peak 45-64 (113 reports)

18-44 67 (30%)
45-64 113 (50%)
65-74 42 (19%)
75+ 2 (1%)

FAERS filings rising toward 2025

2006 2025

Reactions in Death Reports

Death-mentioned subset is HEAVY here (25 reports, 8.4%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
TOXICITY TO VARIOUS AGENTS 8
COMPLETED SUICIDE 6
DEATH 5
INTERSTITIAL LUNG DISEASE 3
CARDIAC ARREST 2
GASTROINTESTINAL HAEMORRHAGE 2
ASPHYXIA 1
CARDIO-RESPIRATORY ARREST 1
CIRCULATORY COLLAPSE 1
DRUG TOXICITY 1
INTENTIONAL OVERDOSE 1
MULTIPLE DRUG OVERDOSE INTENTIONAL 1
SUICIDE ATTEMPT 1
TRANSPLANT 1

Reactions in Hospitalization Reports

Hospitalization is HEAVY (144, 48.2% of the book). Top reactions in those rows:

Reaction Reports
ACUTE KIDNEY INJURY 12
CONDITION AGGRAVATED 11
COMA 10
CYTOLYTIC HEPATITIS 9
DRUG ABUSE 9
HYPOGLYCAEMIA 9
HYPOTENSION 9
OVERDOSE 9
ATRIOVENTRICULAR BLOCK 8
BRADYCARDIA 8
ALCOHOL WITHDRAWAL SYNDROME 7
DEPRESSION 7
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 7
FATIGUE 7
HEPATIC CYTOLYSIS 7
RESPIRATORY DISTRESS 7
TACHYCARDIA 7
AGITATION 6
ASTHENIA 6
CHOLESTASIS 6
How to read acamprosate FAERS figures (TRACE-CASE · DEATH-HEAVY · HOSP-HEAVY)

FAERS holds 299 voluntary reports linked to acamprosate (Campral), 2006-2025. Death is listed on 25 (8.4%). Hospitalization appears on 144 (48.2%). Top co-reported indication: Product Used For Unknown Indication.

Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.

Read with acamprosate

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.